Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Laureate to Manufacture Enobia's Drug Candidate | Contract Pharma

What are you searching for?

Sign in
Breaking News

Laureate to Manufacture Enobia’s Drug Candidate

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Laureate Pharma, Inc. has entered into a cGMP contract manufacturing agreement with Enobia Pharma, a biotechnology company developing an enzyme replacement therapy for the treatment of hypophosphatasia. Under the agreement, Laureate will produce Enobia’s fusion protein for treatment of hypophosphatasia, a rare, and potentially fatal metabolic bone disease characterized by skeletal hypomineralization. Terms of the agreement were not disclosed.

“We are delighted by the confidence Enobia has shown by continuing to utilize our specialized experience in the manufacture of fusion proteins,” said Robert J. Broeze, president and chief executive officer of Laureate. “We have a successful relationship with Enobia and will work with them closely to help them achieve their manufacturing objectives.”

“Our partnership with Laureate is an important component of our manufacturing strategy. We look forward to our partnership with Laureate and advancing our hypophosphatasia program into the clinic,” said Robert Heft, president and chief executive officer of Enobia.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters